Which drug works best for shock? major trial to settle debate

NCT ID NCT07562932

Not yet recruiting Disease control Sponsor: Chonnam National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will compare norepinephrine and dopamine as the first drug given to adults with cardiogenic shock, a life-threatening condition where the heart can't pump enough blood. About 512 participants will be randomly assigned to one of the two drugs. The goal is to see which drug reduces the risk of death or worsening shock within the first month, and causes fewer complications like dangerous heart rhythms or need for a heart pump.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: norepinephrine and dopamine (vasopressor drugs)
What this could lead to: If this trial succeeds, it could show which drug is safer and more effective for stabilizing blood pressure and improving survival in cardiogenic shock.
What could go wrong: This is an early-stage comparison trial; results may not apply to all patients. Both drugs have known risks like arrhythmias, and the study is not yet recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOGENIC SHOCK

Contacts and locations

Locations

Chonnam National University Hospital

Gwangju, 61469, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.